Literature DB >> 22475535

Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells.

Elena Sandalova1, Diletta Laccabue, Carolina Boni, Tsunamasa Watanabe, Anthony Tan, Ho Zi Zong, Carlo Ferrari, Antonio Bertoletti.   

Abstract

BACKGROUND & AIMS: During viral infection, the activities of virus-specific CD8(+) T cells are carefully regulated to prevent severe damage of the infected organs. We investigated the mechanisms that control the functions of activated T cells.
METHODS: We measured the size of the population of activated and proliferating CD8(+) T cells and the functional pattern of CD8(+) T cells specific for the entire hepatitis B virus proteome and for selected heterologous virus (Epstein-Barr virus, human cytomegalovirus, and influenza virus) using blood samples from 18 patients with acute hepatitis B. We analyzed the effects of different modulatory mechanisms, such as inhibitory molecules, suppressive cytokines (interleukin-10), and arginase, on the activities of CD8(+) T cells.
RESULTS: In patients with acute hepatitis B, the expansion of activated and proliferating (HLA-DR/CD38(+), Ki-67(+)/Bcl-2(low)) CD8(+) T cells did not quantitatively match their specific functions ex vivo; virus-specific CD8(+) T cells had functional impairments that were temporally restricted to the acute phase of viral hepatitis. These impairments in function were not limited to HBV-specific CD8(+) T cells but were also observed in CD8(+) T cells with specificities for other viruses. We investigated possible causes of antigen-independent CD8(+) T cell inhibition and found that the increased levels of arginase observed in patients with acute hepatitis could suppress the function of activated, but not resting, CD8(+) T cells.
CONCLUSIONS: The increased level of arginase in patients with acute hepatitis B suppresses the functions of activated CD8(+) T cells. This mechanism might limit the amount of liver damage caused by activated CD8(+) T cells in patients with acute HBV infection.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22475535     DOI: 10.1053/j.gastro.2012.03.041

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  23 in total

Review 1.  Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?

Authors:  Sarene Koh; Antonio Bertoletti
Journal:  Med Microbiol Immunol       Date:  2014-12-16       Impact factor: 3.402

2.  Profiling the repertoire of T-cell receptor beta-chain variable genes in peripheral blood lymphocytes from subjects who have recovered from acute hepatitis B virus infection.

Authors:  Jiezuan Yang; Jiajia Chen; Jianqin He; Yirui Xie; Yixing Zhu; Hongcui Cao; Lanjuan Li
Journal:  Cell Mol Immunol       Date:  2014-07       Impact factor: 11.530

Review 3.  T cell metabolism in chronic viral infection.

Authors:  L J Pallett; N Schmidt; A Schurich
Journal:  Clin Exp Immunol       Date:  2019-05-20       Impact factor: 4.330

Review 4.  Immune Response in Hepatitis B Virus Infection.

Authors:  Anthony Tan; Sarene Koh; Antonio Bertoletti
Journal:  Cold Spring Harb Perspect Med       Date:  2015-07-01       Impact factor: 6.915

5.  Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B.

Authors:  Jang-June Park; David K Wong; Abdus S Wahed; William M Lee; Jordan J Feld; Norah Terrault; Mandana Khalili; Richard K Sterling; Kris V Kowdley; Natalie Bzowej; Daryl T Lau; W Ray Kim; Coleman Smith; Robert L Carithers; Keith W Torrey; James W Keith; Danielle L Levine; Daniel Traum; Suzanne Ho; Mary E Valiga; Geoffrey S Johnson; Edward Doo; Anna S F Lok; Kyong-Mi Chang
Journal:  Gastroenterology       Date:  2015-12-10       Impact factor: 22.682

Review 6.  Liver-resident memory T cells: life in lockdown.

Authors:  Laura J Pallett; Mala K Maini
Journal:  Semin Immunopathol       Date:  2022-04-28       Impact factor: 9.623

Review 7.  A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook.

Authors:  Anna Kramvis; Kyong-Mi Chang; Maura Dandri; Patrizia Farci; Dieter Glebe; Jianming Hu; Harry L A Janssen; Daryl T Y Lau; Capucine Penicaud; Teresa Pollicino; Barbara Testoni; Florian Van Bömmel; Ourania Andrisani; Maria Beumont-Mauviel; Timothy M Block; Henry L Y Chan; Gavin A Cloherty; William E Delaney; Anna Maria Geretti; Adam Gehring; Kathy Jackson; Oliver Lenz; Mala K Maini; Veronica Miller; Ulrike Protzer; Jenny C Yang; Man-Fung Yuen; Fabien Zoulim; Peter A Revill
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-07-20       Impact factor: 73.082

8.  Serum arginase, a biomarker of treatment efficacy in human African trypanosomiasis.

Authors:  Romaric Nzoumbou-Boko; Mariette Dethoua; Fréderic Gabriel; Alain Buguet; Raymond Cespuglio; Pierrette Courtois; Sylvie Daulouède; Bernard Bouteille; Stéphane Ngampo; Ghislain Mpandzou; Silla Semballa; Philippe Vincendeau
Journal:  J Clin Microbiol       Date:  2013-04-03       Impact factor: 5.948

9.  Immunoprevalence and immunodominance of HLA-Cw*0801-restricted T cell response targeting the hepatitis B virus envelope transmembrane region.

Authors:  Anthony T Tan; Pimpayao Sodsai; Adeline Chia; Eglantine Moreau; Melissa H Y Chng; Christine Y L Tham; Zi Zong Ho; Nasirah Banu; Nattiya Hirankarn; Antonio Bertoletti
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

10.  Myeloid Cell Arg1 Inhibits Control of Arthritogenic Alphavirus Infection by Suppressing Antiviral T Cells.

Authors:  Kristina S Burrack; Jeslin J L Tan; Mary K McCarthy; Zhisheng Her; Jennifer N Berger; Lisa F P Ng; Thomas E Morrison
Journal:  PLoS Pathog       Date:  2015-10-05       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.